Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QUINTESSENTIAL: Phase 2 Study of Arlocabtagene Autoleucel in Relapsed or Refractory Multiple Myeloma
jRCT2033240706Phase 2Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- May 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
01
Overview
Phase 2, open-label, single-arm trial of arlocabtagene autoleucel in multiple myeloma (MM), sponsored by Bristol Myers Squibb. Primary endpoint: Best overall response (BOR) of partial response or better. Started May 2025; status: recruiting.
02
Drugs
arlocabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2033240706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033240706.